![Thomas Byrne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Byrne
Direktor/Vorstandsmitglied bei Propella Therapeutics, Inc.
Profil
Thomas Byrne currently works as a Director at Propella Therapeutics, Inc.
Aktive Positionen von Thomas Byrne
Unternehmen | Position | Beginn |
---|---|---|
Propella Therapeutics, Inc.
![]() Propella Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Propella Therapeutics, Inc.
![]() Propella Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore. | Health Technology |